Physician profile
Keely Hooks
NPI 1912305269
$4,958.33
in general payments reported to CMS, 2019-2025
30 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.03 · 2023: $1,274 · 2024: $1,886 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,940.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $577.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $573.71 | 2023-2025 | |
| Novo Nordisk INC | $518.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $512.88 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $504.13 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $288.94 | 2023-2025 | Airsupra, Farxiga, Fasenra |
| Exact Sciences Corporation | $282.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $282.54 | 2023-2025 | |
| Shield Therapeutics INC | $245.71 | 2023-2025 | Accrufer |
| Abbvie INC. | $233.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.65 | 2023-2025 | Xifaxan |
| Abbott Laboratories | $116.66 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $109.45 | 2023-2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $73.60 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $50.52 | 2023-2025 | Qelbree, Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $48.32 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $43.91 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $43.47 | 2023 | Contrave, Nexletol, Nexlizet |
| Noven Therapeutics, LLC | $40.77 | 2024 | Xelstrym |
| Merck Sharp & Dohme LLC | $38.45 | 2025 | Lagevrio, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $35.04 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.68 | 2023-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $28.78 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $23.73 | 2025 | |
| Almatica Pharma LLC | $21.13 | 2024 | Loreev Xr |
| Agios Pharmaceuticals, INC. | $17.37 | 2025 | Pyrukynd |
| Biosense Webster, INC. | $16.86 | 2024 | Carto 3 |
| Pulmonx Corporation | $16.29 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Astellas Pharma US INC | $15.96 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $14.24 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.